Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer
Matthew E. Pollarda, Alan J. Moskowitzb, Michael A. Diefenbachc, Simon J. Hallc
a Department of Urology, UCLA School of Medicine, Los Angeles, CA, USA; b Department of Health Evidence and Policy, Mount Sinai School of Medicine, New York, NY, USA; c Smith Institute for Urology, Hofstra Northwell School of Medicine, Lake Success, NY, USA
Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer
Matthew E. Pollarda, Alan J. Moskowitzb, Michael A. Diefenbachc, Simon J. Hallc
a Department of Urology, UCLA School of Medicine, Los Angeles, CA, USA; b Department of Health Evidence and Policy, Mount Sinai School of Medicine, New York, NY, USA; c Smith Institute for Urology, Hofstra Northwell School of Medicine, Lake Success, NY, USA
摘要 Objective: Treatment options for metastatic castration resistant prostate cancer (mCRPC) have expanded rapidly in recent years. Given the significant economic burden, we sought perform a cost-effectiveness analysis (CEA) of the contemporary treatment paradigm for mCRPC.Methods: We devised a treatment protocol consisting of sipuleucel-T, enzalutamide, abiraterone, docetaxel, radium-223, and cabazitaxel. We estimated number and length of treatments for each therapy using dosing schedules or progression free survival data from published clinical trials. We estimated treatment cost using billing data and Medicare reimbursement values and performed a CEA. Our analysis assumed US$100,000 per life year saved (LYS) as the threshold societal willingness to pay.Results: Incremental cost-effectiveness ratios (ICER) for strategies incorporating sipuleucel-T that were not eliminated by extended dominance exceeded the societal threshold willingnessto-pay of US$100,000 per LYS, the lowest of which was sipuleucel-T+enzalutamide+abiraterone+docetaxel at US$207,714 per LYS. Enzalutamide+abiraterone+docetaxel exhibited the most favorable ICER among strategies without sipuleucel-T at US$165,460 per LYS..Conclusion: Based on the available survival data and current costs of treatment, all treatment strategies greatly exceed a commonly assumed societal willingness-to-pay threshold of US$100,000 per LYS. Improvements in this regard can only come with a reduction in pricing, better tailoring of treatment or significant enhancements in survival with clinical use of treatment combinations or sequences.
Abstract: Objective: Treatment options for metastatic castration resistant prostate cancer (mCRPC) have expanded rapidly in recent years. Given the significant economic burden, we sought perform a cost-effectiveness analysis (CEA) of the contemporary treatment paradigm for mCRPC.Methods: We devised a treatment protocol consisting of sipuleucel-T, enzalutamide, abiraterone, docetaxel, radium-223, and cabazitaxel. We estimated number and length of treatments for each therapy using dosing schedules or progression free survival data from published clinical trials. We estimated treatment cost using billing data and Medicare reimbursement values and performed a CEA. Our analysis assumed US$100,000 per life year saved (LYS) as the threshold societal willingness to pay.Results: Incremental cost-effectiveness ratios (ICER) for strategies incorporating sipuleucel-T that were not eliminated by extended dominance exceeded the societal threshold willingnessto-pay of US$100,000 per LYS, the lowest of which was sipuleucel-T+enzalutamide+abiraterone+docetaxel at US$207,714 per LYS. Enzalutamide+abiraterone+docetaxel exhibited the most favorable ICER among strategies without sipuleucel-T at US$165,460 per LYS..Conclusion: Based on the available survival data and current costs of treatment, all treatment strategies greatly exceed a commonly assumed societal willingness-to-pay threshold of US$100,000 per LYS. Improvements in this regard can only come with a reduction in pricing, better tailoring of treatment or significant enhancements in survival with clinical use of treatment combinations or sequences.
通讯作者:
Simon J. Hall,E-mail address:Shall12@Northwell.edu
E-mail: Shall12@Northwell.edu
引用本文:
Matthew E. Pollard, Alan J. Moskowitz, Michael A. Diefenbach, Simon J. Hall. Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer[J]. Asian Journal of Urology, 2017, 4(1): 37-43.
Matthew E. Pollard, Alan J. Moskowitz, Michael A. Diefenbach, Simon J. Hall. Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer. Asian Journal of Urology, 2017, 4(1): 37-43.
[1] American Cancer Society. Cancer facts & figures. Atlanta:American Cancer Society; 2016. [2] Kirby M, Hirst C, Crawford ED. Characterising the castrationresistant prostate cancer population:a systematic review. Int J Clin Pract 2011;65:1180e92. [3] Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, etal.Docetaxelplusprednisoneormitoxantroneplusprednisone for advanced prostate cancer. N Engl J Med 2004;351:1502e12. [4] Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369:213e23. [5] Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castrationresistant prostate cancer. N Engl J Med 2010;363:411e22. [6] de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011;364:1995e2005. [7] de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment:a randomised open-label trial. Lancet 2010;376:1147e54. [8] Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367:1187e97. [9] Smaletz O, Scher HI, Small EJ, Verbel DA, McMillan A, Regan K, et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002;20:3972e82. [10] Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer:a randomised, double-blind study. Lancet 2011;377:813e22. [11] Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part Ⅱ:treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572e83. [12] Petrylak DP. Examining the pharmacoeconomics of advanced prostate cancer. Renal and Urology News. New York, NY:Haymarket Media Inc; 2011. p. 38e42. [13] Pollack A. New drugs fight prostate cancer, but at high cost. New York Times. New York, NY:The New York Times Company; 2011. [14] Cancer trends progress report-2009/2010 update-costs of cancer care. Available from URL:http://progressreport. cancer.gov/doc_detail.asp? pidZ1&didZ2009&chidZ95&coidZ926&midZ[Accessed 21 December 2011]. [15] Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States:2010e2020. J Natl Cancer Inst 2011;103:117e28. [16] Yap TA, Zivi A, Omlin A, de Bono JS. The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol 2011;8:597e610. [17] Cookson MS, Roth BJ, Dahm P, Engstrom C, Freedland SJ, Hussain M, et al. Castration-resistant prostate cancer:AUA guideline. Available from URL:http://www.auanet.org/education/guidelines/castration-resistant-prostate-cancer. cfm[Accessed 8 May 2013]. [18] Sheikh NA, Petrylak D, Kantoff PW, Dela Rosa C, Stewart FP, Kuan LY, et al. Sipuleucel-T immune parameters correlate with survival:an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother 2013;62:137e47. [19] Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013;368:138e48. [20] Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424e43. [21] Neumann PJ, Rosen AB, Weinstein MC. Medicare and costeffectiveness analysis. N Engl J Med 2005;353:1516e22. [22] Karlsson G, Johannesson M. The decision rules of costeffectiveness analysis. Pharmacoeconomics 1996;9:113e20. [23] Pollack A. New drug for prostate cancer gets F.D.A. Nod. The New York Times. New York:The New York Times Company; 2012. [24] Stokes ME, Black L, Benedict A, Roehrborn CG, Albertsen P. Long-term medical-care costs related to prostate cancer:estimates from linked SEER-Medicare data. Prostate Cancer Prostatic Dis 2010;13:278e84. [25] Penson DF, Moul JW, Evans CP, Doyle JJ, Gandhi S, Lamerato L. The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer:findings from a retrospective analysis of health plan data. J Urol 2004;171:2250e4. [26] Piper NY, Kusada L, Lance R, Foley J, Moul J, Seay T. Adenocarcinoma of the prostate:an expensive way to die. Prostate Cancer Prostatic Dis 2002;5:164e6. [27] Lage MJ, Barber BL, Harrison DJ, Jun S. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008;14:317e22. [28] Hess G, Barlev A, Chung K, Hill JW, Fonseca E. Cost of palliative radiation to the bone for patients with bone metastases secondary to breast or prostate cancer. Radiat Oncol 2012;7:168. [29] Malangone-Monaco E, Foley K, Varker H, Wilson KL, McKenzie S, Ellis L. Prescribing patterns of oral antineoplastic therapies observed in the treatment of patients with advanced prostate cancer between 2012 and 2014:results of an oncology EMR analysis. Clin Ther 2016;38:1817e24. [30] Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 2013;24:1802e7. [31] Badrising S, van der Noort V, van Oort IM, van den Berg HP, Los M, Hamberg P, et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer 2014;120:968e75. [32] Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T, et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 2014;65:30e6. [33] Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C, et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 2013;24:1807e12. [34] SchellhammerPF, Chodak G, WhitmoreJB,Sims R, FrohlichMW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial. Urology 2013;81:1297e302. [35] Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014;371:1028e38. [36] Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, et al. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castrationresistant prostate cancer. JAMA Oncol 2015;1:582e91. [37] Markowski MC, Frick KD, Eshleman JR, Luo J, Antonarakis ES. Cost-savings analysis of AR-V7 testing in patients with metastatic castration-resistant prostate cancer eligible for treatment with abiraterone or enzalutamide. Prostate 2016. http://dx.doi.org/10.1002/pros.23232[Epub ahead of print].
Christopher Hartman, Nikhil Gupta, David Leavitt, David Hoenig, Zeph Okeke, Arthur Smith. Advances in percutaneous stone surgery[J]. Asian Journal of Urology, 2015, 2(1): 26
-32
.
